GSK, CureVac team up to develop vaccine against COVID-19 variants
Britain's GlaxoSmithKline and German biotech firm CureVac have teamed up in a 150 million euro ($180 million) deal to develop a COVID-19 vaccine from next year that could target several variants with one shot.
from bdnews24.com - Home https://ift.tt/2MmpGt6
from bdnews24.com - Home https://ift.tt/2MmpGt6
No comments